Bloomberg News

Retractable Rejected by Top Court on Becton Patent Appeal

January 07, 2013

The U.S. Supreme Court rejected an appeal by Retractable Technologies Inc. (RVP:US) in its patent suit against Becton, Dickinson & Co. (BDX:US) over technology used to protect health-care workers from accidental needle sticks.

Retractable was seeking to overturn a federal appeals court decision that struck down part of a $5 million jury award.

The U.S. Court of Appeals for the Federal Circuit ruled in July that Becton’s 3-milliliter Integra syringe doesn’t violate Retractable’s patents. The appeals court upheld the jury’s separate finding against Becton over its 1-milliliter Integra product. The patents cover Retractable’s VanishPoint-brand syringes, which contain spring-loaded needles.

Retractable, based in Little Elm, Texas, is also pressing an antitrust case against Becton, based in Franklin Lakes, New Jersey.

The case is Retractable Technologies v. Becton Dickinson, 11-1154.

To contact the reporter on this story: Greg Stohr in Washington at gstohr@bloomberg.net

To contact the editor responsible for this story: Steven Komarow at skomarow1@bloomberg.net


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • RVP
    (Retractable Technologies Inc)
    • $4.95 USD
    • 0.11
    • 2.22%
  • BDX
    (Becton Dickinson and Co)
    • $139.34 USD
    • -0.56
    • -0.4%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus